---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-047568"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T13:21:13.424371+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cellectar Biosciences Q1 2025 Net Loss Narrowed to $6.6M; Seeks EMA Conditional Approval for Iopofosine

## Summary
- Net loss for Q1 2025 was $6.6 million ($0.14 per share), compared to $26.6 million ($0.91 per share) in Q1 2024.
- Company seeking conditional EMA approval for iopofosine I 131 in Waldenstrom macroglobulinemia based on CLOVER WaM Phase 2 data with 59% major response rate in BTKi-treated patients.
- Cash and cash equivalents totaled $13.9 million as of March 31, 2025, expected to fund operations into Q4 2025.
- Board engaged Oppenheimer & Co. as exclusive financial advisor to explore strategic alternatives including mergers, acquisitions, or partnerships.
- Planned Phase 3 study for iopofosine I 131 would be a comparator randomized controlled study with 100 patients per arm, dependent on funding.

## SEC filing metadata
- accession: 0001104659-25-047568
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465925047568/0001104659-25-047568-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465925047568/tm2514904d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-047568
- JSON: https://secwatch.observer/filing/0001104659-25-047568.json
- Plain text: https://secwatch.observer/filing/0001104659-25-047568.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.